# Becton Dickinson & Co: Form 10-Q for the period ended Jun 30, 2013

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2013-08-05
- Accepted by EDGAR: Aug 5, 2013, 15:09 ET
- Period: 2013-06-30
- Accession: 0001193125-13-318898
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000119312513318898/d542027d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000119312513318898/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-04-01 to 2013-06-30 | $2.05bn | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2012-10-01 to 2013-06-30 | $5.95bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2013-04-01 to 2013-06-30 | $992.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2012-10-01 to 2013-06-30 | $2.87bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2013-04-01 to 2013-06-30 | $121.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2012-10-01 to 2013-06-30 | $361.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2013-04-01 to 2013-06-30 | $534.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2012-10-01 to 2013-06-30 | $1.54bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2013-04-01 to 2013-06-30 | $404.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2012-10-01 to 2013-06-30 | $1.18bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-04-01 to 2013-06-30 | $34.6m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2012-10-01 to 2013-06-30 | $104.3m | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-04-01 to 2013-06-30 | $87.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2012-10-01 to 2013-06-30 | $267.0m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2013-04-01 to 2013-06-30 | $1.52 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2012-10-01 to 2013-06-30 | $6.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2013-04-01 to 2013-06-30 | $1.55 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2012-10-01 to 2013-06-30 | $6.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2013-04-01 to 2013-06-30 | 198,719,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2012-10-01 to 2013-06-30 | 199,111,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2012-10-01 to 2013-06-30 | $989.3m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2012-10-01 to 2013-06-30 | $339.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2012-10-01 to 2013-06-30 | $289.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2012-10-01 to 2013-06-30 | $406.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2013-06-30 | $1.96bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-06-30 | $5.43bn | us-gaap:AssetsCurrent |
| Total assets | at 2013-06-30 | $11.59bn | us-gaap:Assets |
| Current liabilities | at 2013-06-30 | $1.69bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | at 2013-06-30 | $207.4m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2013-06-30 | $4.72bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2013-06-30 | 194,212,346 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 43,987 characters.

#### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Our business consists of three worldwide business segments – BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives.

#### Overview of Financial Results and Financial Condition

Third quarter revenues of $2.053 billion represented an increase of 3.6% from the same period a year ago, and reflected volume increases of approximately 4.9%, and favorable price impacts, including product mix, of approximately 0.2%, partially offset by unfavorable foreign currency translation of approximately 1.5%. Revenue growth in the third quarter of fiscal year 2013 was driven by our Medical and Diagnostics segments and was attributable to new product sales, growth from acquisitions, sales of safety-engineered products and geographic expansion. Revenue growth also benefitted from the reversal of unfavorable order timing which affected revenues in the second quarter of fiscal year 2013. Revenues in our Biosciences segment benefitted from slight growth in instrument placements in the U.S., but were unfavorably impacted by continued softness in Western European sales due to austerity measures, the timing of government funding in Japan, and the unfavorable timing of Advanced Bioprocessing orders. This unfavorable timing of Advanced Bioprocessing orders, as well as ongoing softness in the Diagnostics segment’s Women’s Health and Cancer platform, unfavorably impacted U.S. revenue growth in the third quarter of fiscal year 2013. International revenues in our Medical and Diagnostics segments reflected continued strength in emerging market sales and strong sales of safety-engineered products. Sales of safety-engineered devices in the United States in the third quarter of 2013 of $301 million increased 5.6% over the prior year’s quarter. International sales of safety-engineered devices of $237 million in the third quarter of 2013 grew 9.9% over the prior year’s period, including an estimated 2.8% unfavorable impact due to foreign currency translation. International safety-engineered device revenue growth continues to be driven by strong growth in the Medical segment, with the largest growth in Western Europe and emerging markets.

We continue to invest in research and development spending, geographic expansion, and new product promotions to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products with higher gross profit margins across our business segments, and continue to improve operating efficiency and organizational effectiveness. The healthcare industry continues to face a challenging economic environment. The current economic conditions and other circumstances have resulted in pricing pressures for some of our products. Continued uncertainty in the research spending environment could adversely affect our Biosciences segment. In other areas of our U.S. business, healthcare utilization is stable but constrained. Additionally, we have experienced constrained healthcare utilization in Europe due to continued macroeconomic challenges in that region, although we currently view the environment as stable.

In addition to the economic conditions in the United States and elsewhere, numerous other factors can affect our ability to achieve our goals including, without limitation, increased competition and healthcare reform initiatives. For example, the U.S. Patient Protection and Affordable Care Act contains the medical device excise tax that, effective January 1, 2013, imposes a 2.3% tax on certain U.S. sales of medical devices. The impact of this tax on our results for the three and nine-month periods ended June 30, 2013 are further discussed below. We currently estimate the full year fiscal 2013 impact from this excise tax (impacting only three quarters for fiscal year 2013) will be about $40 to $45 million.

Our financial position remains strong, with cash flows from operating activities totaling $989 million in the first nine months of 2013. At June 30, 2013, we had $2.3 billion in cash and equivalents and short-term investments. Cash outflows relating to acquisitions primarily represented the purchase of Safety Syringes, Inc. (“Safety Syringes”), a privately held California-based company that specializes in the development of anti-needlestick devices for prefilled syringes for $124 million, net of cash acquired. Cash flows relating to acquisitions also included the purchase of Cato Software Solutions (“Cato”), a privately held Austria-based manufacturer of a suite of comprehensive medication safety software solutions, for $14 million, net of cash acquired. Refer to Note 9 in the Notes to Condensed Consolidated Financial Statements for further discussion of these acquisitions. Cash inflows from divestitures of $736 million represented the sale of Biosciences’ Discovery Labware unit, excluding its Advanced Bioprocessing platform. Refer to Note 10 in the Notes to Condensed Consolidated Financial Statements for additional information. Also, we continued to return value to our shareholders in the form of share repurchases and dividends. During the first nine months of 2013, we repurchased $406 million of our common stock and paid cash dividends of $290 million.

We face currency exposure each reporting period that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. We evaluate our results of operations on both an as reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period reported results. From time to time, we may purchase forward contracts and options to partially protect against adverse foreign exchange rate movements. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. We do not enter into derivative instruments for trading or speculative purposes. For further discussion, refer to Note 12 in the Notes to Condensed Consolidated Financial Statements.

Comparisons of income from continuing operations between the third-quarter and nine-month periods of fiscal year 2013 and the prior-year periods of fiscal year 2012 are affected by the following items that are reflected in our financial results:

- During the third-quarter and nine-month periods of fiscal year 2013, we recorded a pre-tax charge of $22 million, or $0.07 diluted earnings per share from continuing operations, in selling and administrative expense for the pending litigation settlement related to the indirect purchaser antitrust class action cases as disclosed in Note 5 in the Notes to Condensed Consolidated Financial Statements.
- During the third quarter of fiscal year 2013, we recorded a pre-tax charge of $13 million, or $0.04 diluted earnings per share from continuing operations, in selling and administrative expense relating to the medical device excise tax discussed above. The pre-tax charge relating to this tax was $27 million, or $0.09 diluted earnings per share from continuing operations, for the nine-month period of fiscal year 2013.

#### Results of Operations

#### Revenues

Refer to Note 6 in the Notes to Condensed Consolidated Financial Statements for segment financial data.

#### Medical Segment

Third quarter revenues of $1.140 billion increased 6.6% over the prior year’s quarter, which reflected an estimated unfavorable foreign currency translation impact of 1.3%.

The following is a summary of third quarter Medical revenues by organizational unit:

| (millions of dollars) | Three months ended June 30, 2013 | 2012 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Medical Surgical Systems | $561 | $532 | 5.5% | (1.1)% |
| Diabetes Care | 250 | 233 | 7.3% | (2.1)% |
| Pharmaceutical Systems | 330 | 306 | 8.0% | (1.2)% |
| Total Revenues\* | $1,140 | $1,070 | 6.6% | (1.3)% |

\* Amounts may not add due to rounding

Medical segment revenue growth was driven by strong international sales, strong sales of safety-engineered products and the reversal of unfavorable order timing which affected revenues in the second quarter of fiscal year 2013. Solid revenue growth in the Medical Surgical Systems unit was largely attributable to sales in emerging markets and strong international sales of safety-engineered products, including the BD PhaSeal™ System. Revenue growth in the Diabetes Care unit reflected strong sales of pen needles, including the BD Ultra-Fine™ Nano and PentaPoint™ products as well as the BD AutoShield™ Duo Pen Needle. Revenue growth in Diabetes Care also reflected the favorable timing of orders. Revenue growth in the Pharmaceutical Systems unit benefitted from the favorable timing of orders and from revenue growth attributable to the acquisition of Safety Syringes in the first quarter of fiscal year 2013. Global sales of safety-engineered products were $268 million, compared with $240 million in the prior year’s quarter, and included an estimated $3 million unfavorable impact due to foreign currency translation. Total Medical revenues for the nine-month period ended June 30, 2013 increased by 4.7% from the prior-year nine-month period, including an estimated 1.1% unfavorable impact from foreign currency translation. For the nine-month period ended June 30, 2013, global sales of safety-engineered products were $776 million, compared with $716 million in the prior year’s period, and included an estimated $6 million unfavorable impact due to foreign currency translation.

Medical operating income for the third quarter was $334 million, or 29.3% of Medical revenues, compared with $324 million, or 30.3% of segment revenues, in the prior year’s quarter. Gross profit margin was higher in the current quarter than the third quarter of 2012 primarily due to lower manufacturing costs resulting from Project ReLoCo, a global, cross-functional business initiative to drive sustained low-cost capability primarily benefitting Medical Surgical Systems. Gross profit margin was also favorably impacted by pricing on certain product lines. These favorable impacts on gross profit margin were partially offset by unfavorable foreign currency translation. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Medical revenues in the third quarter of 2013 was higher than in the third quarter of 2012. This increase reflected the medical device excise tax previously discussed, as well as increased spending for expansion in emerging markets. Research and development expenses for the quarter increased $5 million, or 12% above the prior year’s period, reflecting ongoing investment in new products and platforms. Segment operating income for the nine-month period was $913 million, or 28.7% of Medical revenues, compared with $863 million, or 28.4%, in the prior year’s period.

#### Diagnostics Segment

Third quarter revenues of $655 million increased 2.0% over the prior year’s quarter, which reflected an estimated unfavorable foreign currency translation impact of 1.6%.

The following is a summary of third quarter Diagnostics revenues by organizational unit:

| (millions of dollars) | Three months ended June 30, 2013 | 2012 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $345 | $333 | 3.4% | (1.2)% |
| Diagnostic Systems | 310 | 309 | 0.5% | (2.0)% |
| Total Revenues | $655 | $642 | 2.0% | (1.6)% |

Diagnostics segment revenue growth was driven by solid sales in the Preanalytical Systems unit. Revenues in the Diagnostic Systems unit were unfavorably impacted by the timing of lab automation system installations globally, as well as ongoing softness in the United States in the Women’s Health and Cancer platform due to guidelines providing for increased Pap smear testing intervals. Global sales of safety-engineered products in the Preanalytical Systems unit totaled $270 million, compared with $261 million in the prior year’s quarter, and included an estimated $3 million unfavorable impact due to foreign currency translation. Total Diagnostics revenues for the nine-month period ended June 30, 2013 increased by 3.9% from the prior-year nine-month period, including an estimated 1.0% unfavorable impact from foreign currency translation. For the nine-month period ended June 30, 2013, global sales of safety-engineered products in the Preanalytical Systems unit were $788 million, compared with $761 million in the prior year’s period, and included an estimated $6 million unfavorable impact due to foreign currency translation.

Diagnostics operating income for the third quarter was $159 million, or 24.2% of Diagnostics revenues, compared with $174 million, or 27.0% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter than in the prior year’s quarter primarily due to amortization expense related to the Jaguar Plus Platform, an in-process research development project that was acquired in the Company’s fiscal year 2010 acquisition of HandyLab, Inc. and completed in the fourth quarter of fiscal year 2012. Gross profit margin in the third quarter of 2013 was also unfavorably impacted by foreign currency translation. These unfavorable impacts on gross profit margin were partially offset by pricing on certain product lines. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Diagnostics revenues in the third quarter of 2013 was higher than in the third quarter of 2012. This increase reflected the medical device excise tax previously discussed, as well as increased spending for expansion in emerging markets and spending for new product launches. Research and development expenses in the third quarter of 2013 were flat compared with the prior year’s period, and reflected the timing of expenses in fiscal year 2013. Segment operating income for the nine-month period was $473 million, or 24.1% of Diagnostics revenues, compared with $497 million, or 26.3%, in the prior year’s period.

#### Biosciences Segment

Third quarter revenues of $257 million decreased 4.2% over prior year quarter revenues of $268 million, which reflected an estimated unfavorable foreign currency translation impact of 1.7%. Biosciences revenues in the third quarter reflected slight growth in instrument placements in the U.S. but were unfavorably impacted by weaker Western European sales due to austerity measures, the timing of government funding in Japan, and unfavorable timing of Advanced Bioprocessing orders. For the nine-month period ended June 30, 2013, total Biosciences revenues decreased by 0.6% from the prior-year nine-month period, including an estimated 1.5% unfavorable impact from foreign currency translation.

Biosciences operating income for the third quarter was $58 million, or 22.6% of Biosciences revenues, compared with $67 million, or 25.0% of segment revenues, in the prior year’s quarter. Gross profit margin as a percent of Biosciences revenues, was lower in the current quarter than in the prior year’s quarter primarily due to unfavorable foreign currency translation. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Biosciences revenues in the third quarter of 2013 was higher compared with the prior year’s quarter. This increase reflected the medical device excise tax previously discussed as well as increased spending for expansion in emerging markets. Research and development expenses in the third quarter of 2013 increased by $2 million, or 8% above the prior year’s period, and reflected increased investment in new products and platforms. Segment operating income for the nine-month period was $195 million, or 24.3% of Biosciences revenues, compared with $200 million, or 24.7%, in the prior year’s period.

#### Geographic Revenues

Revenues in the United States for the third quarter of $848 million represented an increase of 1.3% over the prior year’s quarter. We view the environment in the U.S. as constrained, but stable. U.S. revenue growth in the Medical segment was partially driven by the reversal of the unfavorable timing of orders in the Pharmaceutical Systems and Diabetes Care units which affected revenues in the second quarter of fiscal year 2013. U.S. revenues in the Medical segment also reflected growth attributable to the acquisition of Safety Syringes in the first quarter of fiscal year 2013. Diagnostics segment revenue growth in the United States was unfavorably impacted by a decline in our Women’s Health and Cancer platform sales due to guidelines providing for increased Pap smear testing intervals. Biosciences revenue growth in the United States reflected slight growth in instrument placements that was more than offset by the unfavorable timing of Advanced Bioprocessing orders. We remain cautious about the U.S. environment for this segment given the continued uncertainty around U.S. government research funding due to the impact of automatic U.S. government spending cuts, or sequestration, that went into effect in March 2013.

International revenues for the third quarter of $1.205 billion represented an increase of 5.3% over the prior year’s quarter, including a 2.6% unfavorable impact due to foreign currency translation. International revenues for the third quarter of 2013 reflected continued strength in emerging market revenues and strong sales of safety-engineered products for the Medical and Diagnostics segments. International Biosciences revenue growth was unfavorably impacted by weaker sales in Western Europe due to austerity measures and the timing of government funding in Japan.

#### Gross Profit Margin

Gross profit margin was 51.6% for the third quarter, compared with 52.2% for the comparable prior-year period. The decrease in gross profit margin reflected 60 basis points primarily relating to unfavorable foreign currency translation. Operating performance was favorably impacted by approximately 60 basis points primarily due to lower manufacturing costs from continuous improvement projects, such as Project ReLoCo, and pricing on certain product lines. These favorable impacts were offset by 60 basis points primarily due to, among other items, amortization of intangibles associated with recent acquisitions and higher start-up costs.

Gross profit margin was 51.8% in the nine-month period of 2013, compared with 51.4% for the comparable prior-year period. The increase primarily reflected operating performance. Gross profit margin was favorably impacted by approximately 80 basis points primarily due to lower manufacturing costs from continuous improvement projects and lower raw material costs. Gross profit margin was also favorably impacted by approximately 30 basis points due to the Company’s change in useful lives of certain machinery and equipment assets. Gross profit margin was adversely affected by approximately 70 basis points primarily due to, among other items, amortization of intangibles associated with recent acquisitions and pricing pressures on certain product lines.

#### Selling and Administrative Expense

Selling and administrative expense was 26.0% of revenues for the third quarter, compared with 23.7% for the prior year’s period. Aggregate expenses for the third quarter reflected an increase in core spending of $32 million, primarily relating to expansion of our business in emerging markets and higher expenses resulting from recent acquisitions. Aggregate expenses for the third quarter of 2013 also reflected the $22 million charge for the pending litigation settlement previously discussed and $13 million related to the medical device excise tax also previously discussed. Selling and administrative expenses in the current year’s period also reflected an unfavorable comparison to the prior-year period of $5 million due to the timing of litigation costs in the current quarter. These increases were partially offset by favorable foreign currency translation of $7 million.

Selling and administrative expense was 25.9% of revenues for the nine-month period of fiscal year 2013, compared with 25.1% for the prior year’s period. Aggregate expenses for the nine-month period reflected an increase in core spending of $94 million, primarily relating to expansion of our business in emerging markets and higher expenses resulting from recent acquisitions. Aggregate expenses for the nine-month period also reflected the $22 million charge for the pending litigation settlement and $27 million related to the medical device excise tax. These increases were partially offset by favorable foreign currency translation of $16 million and a decrease in deferred compensation expense of $4 million. This change in the deferred compensation liability is further discussed below. Selling and administrative expenses in the current year’s nine-month period also reflected a favorable comparison to the prior-year period of $17 million due to the timing of litigation costs. We expect such costs to increase in the fourth quarter of fiscal year 2013 in anticipation of the RTI trial in September 2013. For further discussion, refer to Note 5 in the Notes to Condensed Consolidated Financial Statements.

#### Research and Development Expense

Research and development expense was $121 million, or 5.9% of revenues, for the third quarter, representing an increase of 5.3% compared with the prior year’s amount of $115 million, or 5.8% of revenues. The increase in research and development expense compared with the prior year’s quarter reflected increased investment in new products and platforms primarily within the Medical and Biosciences segments. Research and development expense was $362 million, or 6.1% of revenues, for the nine-month period in the current year, compared with the prior year’s amount of $344 million, or 6.0% of revenues. The current nine-month period’s increase in research and development expense compared with the prior year’s period reflected increased investment in new products and platforms primarily within the Medical and Diagnostics segments.

#### Non-Operating Expense and Income

Interest income and interest expense in the third quarter of fiscal year 2013 were comparable to the prior-year period’s amounts. Interest income was $26 million in the nine-month period of 2013, compared with $38 million in the prior year’s period. The decrease in interest income in the nine-month period of fiscal year 2013 compared with the prior year’s period reflected the impact of lower rates on investments outside the U.S. and lower investment gains on assets related to our deferred compensation plan. The offsetting movements in the deferred compensation plan liability were recorded in selling and administrative expense. Interest expense in the nine-month period of fiscal year 2013 was $104 million, compared with $99 million in the prior year’s period. The increase in interest expense in the nine-month period of fiscal year 2013 primarily reflected higher levels of long-term fixed-rate debt.

#### Income Taxes

The income tax rate was 23.0% for the third quarter, compared with the prior year’s rate of 25.6%. The nine-month tax rate was 24.2% compared with the prior year’s rate of 24.8%. The tax rate for the third quarter of fiscal year 2013 reflected the favorable impact of the reinstatement of the U.S. research and development tax credit on the annual tax rate whereas the tax rate for the prior year’s quarter reflected other items that vary from year to year. The tax rate for the year-to-date period ending June 30, 2013 reflected the reinstatement of the U.S. research and development tax credit. The income tax rate in the first nine months of 2012 reflected the favorable impact of various tax settlements in multiple jurisdictions.

#### Income from Continuing Operations and Diluted Earnings Per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations for the third quarter of 2013 were $292 million and $1.47, respectively. Income from continuing operations and diluted earnings per share from continuing operations for the prior year’s third quarter were $312 million and $1.52, respectively. The charge relating to the pending litigation settlement decreased income from continuing operations by $14 million, or $0.07 diluted earnings per share. The medical device excise tax decreased income from continuing operations for the third quarter of fiscal year 2013 by $9 million, or $0.04 diluted earnings per share. The current quarter’s diluted earnings per share from continuing operations reflected an estimated $0.05 unfavorable impact due to foreign currency translation.

For the nine-month periods, income from continuing operations and diluted earnings per share from continuing operations were $838 million and $4.21, respectively, in 2013 and $835 million and $3.95, respectively, in 2012. The charge relating to the pending litigation settlement decreased income from continuing operations for the nine-month period of 2013 by $14 million, or $0.07 diluted earnings per share. The medical device excise tax decreased income from continuing operations for the nine-month period of fiscal year 2013 by $18 million, or $0.09 diluted earnings per share. The current nine-month period’s diluted earnings per share from continuing operations reflected an estimated $0.05 unfavorable impact due to foreign currency translation.

#### Liquidity and Capital Resources

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs in fiscal year 2013. Normal operating needs in fiscal year 2013 include working capital, capital expenditures, cash dividends and common stock repurchases. Net cash provided by continuing operating activities was $989 million during the first nine months of 2013, compared with $1.136 billion in the same period in 2012. The current period change in operating assets and liabilities was a net use of cash and primarily reflected higher levels of inventory and lower levels of accounts payable and accrued expenses, partially offset by lower levels of prepaid expenses. Net cash provided by continuing operating activities in the first nine months of 2013 was reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of approximately $138 million. Net cash provided by continuing operating activities in the prior-year period was also reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of approximately $100 million.

Net cash provided by continuing investing activities for the first nine months of the current year was $296 million, compared with net cash used for continuing investing activities of $644 million in the prior-year period. The current period’s net cash provided by continuing investing activities included approximately $736 million of net proceeds from the sale of the Discovery Labware disposal group in the first quarter of fiscal year 2013. Cash outflows relating to acquisitions were $136 million in the first nine months of the current year, primarily as a result of the Company’s acquisitions of Safety Syringes and Cato in the first and second quarters of fiscal year 2013, respectively. Cash outflows relating to acquisitions were $51 million in the prior year’s period as a result of the Company’s second quarter 2012 acquisition of KIESTRA. Capital expenditures were $339 million in the first nine months of 2013 and $313 million in the same period in 2012.

Net cash used for financing activities for the first nine months of the current year was $830 million, compared with $56 million in the prior-year period. The current period’s net cash used for financing activities reflected the repayment of $200 million of 4.55% notes due on April 15, 2013. The prior period’s net cash provided by financing activities included the proceeds from $500 million of 5-year 1.75% notes and $1 billion of 10-year 3.125% notes issued on November 3, 2011.

For the first nine months of the current year, we repurchased approximately 5 million shares of our common stock for $406 million, compared with approximately 16.7 million shares of our common stock for $1.25 billion in the prior-year period. Aggregate common stock repurchases are estimated to be between $450 and $500 million for the full fiscal year 2013, subject to market conditions. At June 30, 2013, a total of approximately 3.2 million common shares remained available for purchase under the Board of Directors’ July 2011 repurchase authorization.

At June 30, 2013, total worldwide cash and short-term investments were approximately $2.3 billion, of which $2.0 billion was held in jurisdictions outside of the United States. We regularly review the amount of cash and short-term investments held outside of the United States and currently intend to use most of such amounts to fund our international operations and their growth initiatives. However, if these amounts were moved out of these jurisdictions or repatriated to the United States, there could be adverse tax consequences. It is anticipated that cash above the Company’s normal amount of annual repatriations may be repatriated out of fiscal year 2013 earnings. The cost of such potential incremental cash repatriations is not anticipated to materially impact the Company’s forecasted effective tax rate for the full fiscal year 2013.

As of June 30, 2013, total debt of $4 billion represented 45.4% of total capital (shareholders’ equity, net non-current deferred income tax liabilities, and debt), versus 49.7% at September 30, 2012. Short-term debt decreased to 5.2% of total debt at the end of June 30, 2013, from 9.7% at September 30, 2012 due to the repayment of $200 million of 4.55% notes due on April 15, 2013.

We have in place a commercial paper borrowing program that is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were $200 million at June 30, 2013. We have available a $1 billion syndicated credit facility with an expiration date of May 2017. This credit facility, under which there were no borrowings outstanding at June 30, 2013, provides backup support for our commercial paper program and can also be used for other general corporate purposes. It includes a provision that enables BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility, for a maximum aggregate commitment of $1.5 billion. The credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio (ratio of earnings before income taxes, depreciation and amortization to interest expense) of not less than 5-to-1 for the most recent four consecutive fiscal quarters. On the last eight measurement dates, this ratio has ranged from 13-to-1 to 19-to-1. In addition, we have informal lines of credit outside the United States.

#### Government Receivables

Accounts receivable balances include sales to government-owned or government-supported healthcare facilities in several countries, which are subject to delays. Payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. Deteriorating credit and economic conditions in parts of Western Europe, particularly in Italy and Spain, may continue to increase the average length of time it takes us to collect our accounts receivable in certain regions within these countries. Outstanding governmental receivable balances, net of reserves, in Italy and Spain at June 30, 2013 were $79 million and $53 million, respectively.

We continually evaluate all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on our financial position or liquidity.

#### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future — including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results — are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in our 2012 Annual Report on Form 10-K.

- Continued weakness in the global economy and financial markets, and the potential adverse effect on the cost of operating our business, the demand for our products and services, prices for our products and services due to increases in pricing pressure, or our ability to produce our products, including the impact on developing countries. In particular, deficit reduction efforts or other adverse changes in the availability of

government funding for healthcare and research, particularly in the U.S. and Europe, could further weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales. In that regard, in the U.S., automatic spending cuts, or sequestration that went into effect in March 2013, are impacting government healthcare spending and research funding.

- The consequences of the Patient Protection and Affordable Care Act in the United States, which implemented an excise tax on U.S. sales of certain medical devices, and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect BD’s business.
- Future healthcare reform in the countries in which we do business may also involve changes in government pricing and reimbursement policies or other cost containment reforms.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment (including changes in reimbursement practices by third party payors).
- Our ability to penetrate developing and emerging markets, which depends on local economic and political conditions and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities, distribution networks, sales equipment and technology.
- Regional, national and foreign economic factors, including inflation, deflation, fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls and licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, including increased enforcement activity by the FDA.
- Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
- The effects of events that adversely impact our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants) or our ability to source materials or components from suppliers that are needed for such manufacturing, including pandemics, natural disasters, or environmental factors.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain sub-assemblies and finished goods, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies or changes in the regulatory process (including potential 510(k) reforms) may also delay product launches and increase development costs.
- Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
- Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.
- Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected volumes and sales of many product types, some of which are more profitable than others.
- Our ability to implement our ongoing upgrade of our enterprise resource planning system, as any delays or deficiencies in the design and implementation of our upgrade could adversely affect our business.
- Security breaches of our computer and communications systems, including computer viruses, “hacking” and “cyber-attacks,” which could impair our ability to conduct business, or result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners.
- Pending and potential future litigation or other proceedings adverse to BD, including antitrust claims, product liability claims, environmental claims and patent infringement claims, and the availability or collectability of insurance relating to any such claims.
- The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
- The effects, if any, of governmental and media activities regarding the business practices of group purchasing organizations, which negotiate product prices on behalf of their member hospitals with BD and other suppliers.
- The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders and expropriation of assets by a government, including the recent civil unrest in parts of the Middle East.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 1,019 characters.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of June 30, 2013. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. There were no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2013 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

## Risk factors

As filed, 1,969 characters.

There have been no material changes to the risk factors disclosed in Part 1, Item 1A, of our 2012 Annual Report on Form 10-K except as provided below.

Breaches of our information technology systems could have a material adverse effect on our operations. We rely on information technology systems to process, transmit, and store electronic information in our day-to-day operations. Like many multinational corporations, our information technology systems have been subjected to computer viruses or other malicious codes, unauthorized access attempts, and cyber- or phishing-attacks, and we expect to be subject to similar attacks in the future. We also store certain information with third parties that could be subject to these types of attacks. These attacks could result in our intellectual property and other confidential information being lost or stolen, disruption of our operations, and other negative consequences, such as increased costs for security measures or remediation costs, and diversion of management attention. Recently, we became aware that certain of our information systems have been compromised by an external threat. We have retained an independent third-party security firm to help us assess the nature and extent of the unauthorized access, and implemented additional security measures while we continue to investigate the matter. To date, this incident has not caused any material interruption of or damage to our information systems, material disruption of our operations or material increases in our operating expenses due to the costs of the additional security measures. While we are implementing additional protective measures to reduce the risk of and detect future cyber incidents, cyber-attacks are becoming more sophisticated and frequent, and the techniques used in such attacks change rapidly. There can be no assurances that our protective measures will prevent future attacks that could have a significant impact on our business.

Filed Aug 5, 2013.
Source: SEC EDGAR, the filing index for accession 0001193125-13-318898. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
